Dr. Veena Charu
Claim this profilePacific Cancer Medical Center
Area of expertise
Lymphoma
Veena Charu has run 4 trials for Lymphoma. Some of their research focus areas include:
Mixed-Cell Lymphoma
Veena Charu has run 2 trials for Mixed-Cell Lymphoma.
Affiliated Hospitals
Pacific Cancer Medical Center
Pacific Cancer Medical Center, Inc.
Clinical Trials Veena Charu is currently running
Tucatinib + Trastuzumab + Chemotherapy
for Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
Recruiting
2 awards
Phase 3
Pirtobrutinib vs Ibrutinib
for Chronic Lymphocytic Leukemia
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib monotherapy in treatment-naïve participants with CLL/SLL with 17p deletions. Participation could last up to six years for Part 1. Participation could last up to 2 years for Part 2.
Recruiting
2 awards
Phase 3
More about Veena Charu
Clinical Trial Related
6 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Veena Charu has experience with
- Orelabrutinib (ICP-022)
- NUV-422
- Fulvestrant
- HMPL-523
- HMPL-689
- Crofelemer
Breakdown of trials Veena Charu has run
Lymphoma
Chronic Lymphocytic Leukemia
Central Nervous System Hodgkin Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Veena Charu specialize in?
Veena Charu focuses on Lymphoma and Mixed-Cell Lymphoma. In particular, much of their work with Lymphoma has involved Stage II patients, or patients who are Stage I.
Is Veena Charu currently recruiting for clinical trials?
Yes, Veena Charu is currently recruiting for 2 clinical trials in Anaheim California. If you're interested in participating, you should apply.
Are there any treatments that Veena Charu has studied deeply?
Yes, Veena Charu has studied treatments such as Orelabrutinib (ICP-022), NUV-422, Fulvestrant.
What is the best way to schedule an appointment with Veena Charu?
Apply for one of the trials that Veena Charu is conducting.
What is the office address of Veena Charu?
The office of Veena Charu is located at: Pacific Cancer Medical Center, Anaheim, California 92801-1824 United States. This is the address for their practice at the Pacific Cancer Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.